TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02630342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mock MRI scanner
Description: Using a mock scanner for preparation for MRI

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mock MRI scanner
Description: Using a mock scanner for preparation for MRI

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preparation materials
Description: links to online videos about MRI, audio files with scanner noises, and a childrens book about MRI scan.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preparation materials
Description: links to online videos about MRI, audio files with scanner noises, and a childrens book about MRI scan.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preparation materials
Description: links to online videos about MRI, audio files with scanner noises, and a childrens book about MRI scan.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child Life Specialist preparation
Description: Child Life Therapist will coordinate the prepartion of the child

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Review Preparation Materials
Description: Review of preparation materials at the hospital with member of research team
Study: NCT02451579

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antihistamine Cetirizine Hydrochloride
Description: Prophylactic use of antihistamine prior to and following topical 5-aminolevulonic acid photodynamic therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Use of placebo prior to and following topical 5-aminolevulonic acid photodynamic therapy
Study: NCT02937194

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal oral health instruction + pamphlets distribution
Description: Personal oral health instruction (OHI) and oral health pamphlets distribution

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pamphlets distribution
Description: Oral health pamphlets distribution
Study: NCT01992133

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03126526

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food specific Inhibitory control training
Description: It involves a go/no-go task in which participants are requested to respond by clicking a particular button when a specific stimulus appears and requested to withhold their response when another particular stimulus appears. Stimuli in this intervention include photos of food and non-food.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation intentions
Description: It involves designing if-then strategies of behaviour. Participants will be asked to describe situations in which they feel they are more prone to behave in a way that is not congruent to their long term goals, and then to plan strategies to behave differently when faced with this situation in the future.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Implementation intentions
Description: It involves designing if-then strategies of behaviour. Participants will be asked to describe situations in which they feel they are more prone to behave in a way that is not congruent to their long term goals, and then to plan strategies to behave differently when faced with this situation in the future.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General inhibitory control training
Description: It involves a go/no-go task in which participants are requested to respond by clicking a particular button when a specific stimulus appears and requested to withhold their response when another particular stimulus appears. Stimuli in this intervention include only non-food pictures.
Study: NCT00711425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsseoSpeed™
Description: OsseoSpeed™, all dimensions
Study: NCT03686098

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary soy
Description: Soy isoflavones delivered through diet, assisted by a detailed food guide for locally available soy-based foods.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy Supplement
Description: Soy isoflavones delivered in extracted form
Study: NCT03579420

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief lifestyle program
Description: 3-session program for modification of lifestyle habits (exercise and diet)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional lifestyle program
Description: 6-session program for modification of lifestyle habits (exercise and diet)
Study: NCT02445118

Intervention type: OTHER
Intervention: Adipose Allograft Matrix (AAM) injection
Description: Adipose Allograft Matrix (AAM) injection, Non-dominant wrist
Study: NCT01943513

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB023
Description: Intravenous (IV) infusions

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study: NCT00630851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil (Aricept)
Description: Donepezil (Aricept) 5 mg tablet orally once daily for 30 days, followed by 10 mg tablet orally once daily to complete 6 months of treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets orally once daily for 6 months
Study: NCT00396994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low magnitude mechanical stimulation
Description: 10 minutes per day of low magnitude mechanical stimulation using a vibrating platform set at 0.3 g and 30 Hz

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham low magnitude mechanical stimulation
Description: 10 minutes per day of low magnitude mechanical stimulation using a sham vibrating platform
Study: NCT04257448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Powder for solution for infusion; Intravenous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Concentrate for solution for infusion; Intravenous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide capsule
Description: Hard capsule for oral use
Study: NCT03251495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaxchora
Description: Vaxchora is a live attenuated cholera vaccine that provides immunity against V. cholerae serogroup O1. Participants will receive one single oral dose of 100 mL.
Study: NCT03141827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin 40 IU, nasal spray, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, nasal spray, single dose
Study: NCT01079273

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: egg-derived A/H1N1 pandemic influenza vaccine
Description: One 0.50 mL IM dose injection (7.5 µg of vaccine + 9.75 mg MF59)
Study: NCT02903251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal oxytocin spray
Description: 6 insufflations (24 IU of oxytocin total) given twice daily, day 1-3. 2 insufflations (8 IU of oxytocin total) as needed, max thrice daily, day 3-30.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: intranasal spray without oxytocin
Description: 6 insufflations (24 IU of placebo total) given twice daily, day 1-3. 2 insufflations (8 IU of placebo total) as needed, max thrice daily, day 3-30.
Study: NCT02847806

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Estradiol (Insulin sensitivity)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Estradiol (Insulin sensitivity)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Testosterone (Insulin sensitivity)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Testosterone (Insulin sensitivity)
Study: NCT04121390

Intervention type: BEHAVIORAL
Intervention: Newborn Parenting Class
Description: Newborn Parenting Class designed by Mount Sinai Parenting Center. The class is 1-hour long and taught be pediatric attending and residents to all families who deliver well babies at Mount Sinai.
Study: NCT02320942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: The semi-supervised intervention is a progressive program with a goal of three aerobic and two resistance exercise sessions per week. Aerobic exercise will consist of 20-40 minutes of bicycling using a stationary bike located on CP6 (supervised or un-supervised) or brisk walking at home. Resistance exercise will include exercise for the upper and lower extremities with stretch bands. Patients will complete at least one supervised aerobic and resistance session per week with the exercise trainer and complete a daily log of their exercise, including adherence, adverse events and symptoms.
Study: NCT02786238

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Behavioral Treatment (SBT)
Description: See description of treatment arm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance-Based Treatment (ABT)
Description: See description of treatment arm. \*\*Cherokee Nation members receive only the ABT intervention as they are in an open, feasibility trial and are not randomized.\*\*
Study: NCT01211548

Intervention type: OTHER
Intervention: contrast CTA of the CAP
Description: CT coronary angiography results will be reported for all patients by adjudicators blinded to their inclusion in the study.
Study: NCT00946257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Otelixizumab
Description: A humanized, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb) directed against the ε domain of the human lymphocyte antigen CD3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Otelixizumab
Description: A humanized, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb) directed against the ε domain of the human lymphocyte antigen CD3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Otelixizumab
Description: A humanized, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb) directed against the ε domain of the human lymphocyte antigen CD3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Otelixizumab
Description: A humanized, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb) directed against the ε domain of the human lymphocyte antigen CD3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Otelixizumab
Description: A humanized, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb) directed against the ε domain of the human lymphocyte antigen CD3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Otelixizumab
Description: A humanized, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb) directed against the ε domain of the human lymphocyte antigen CD3.
Study: NCT02128048

Intervention type: DEVICE
Intervention: Assessment of body composition and muscle function
Description: Assessment of body composition by DEXA and BIA Measurement of muscle function by hand-grip dynamometer and physical tests Comparison between quitters and continued smokers
Study: NCT01204580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLIMEPIRIDE + METFORMIN
Description: Pharmaceutical form: film coated tablet Route of administration: oral Dose regimen: 1 tablet of 1/250 mg per day
Study: NCT03159156

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Applied Tension
Description: Described above.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Respiration Control
Description: Described above.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Applied Tension/Respiration Control
Description: Described above.
Study: NCT01038570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syntocinon®/- Spray
Description: 3 sprays corresponding to 24 IU in each nostril

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiological serum (Sodium chloride)
Description: Sodium chloride 0.9 % (0.3 ml) in each nostril
Study: NCT01984242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody
Description: Atezolizumab will be administered according to the dosage schedule mentioned in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody
Description: Atezolizumab will be administered according to the dosage schedule mentioned in the arm description.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody
Description: Atezolizumab will be administered according to the dosage schedule mentioned in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered according to the dosage schedule mentioned in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered according to the dosage schedule mentioned in the arm description.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab will be administered according to the dosage schedule mentioned in the arm description.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: Sunitinib will be administered according to the dosage schedule mentioned in the arm description.
Study: NCT00948675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Induction therapy: 500 milligrams/square meter (mg/m²) given intravenously every 21 days for 4 cycles. Maintenance therapy: 500 mg/m² given intravenously every 21 days until disease progression or treatment discontinuation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Induction Therapy (every 21 days for 4 cycles): Area Under the Curve (AUC) 6 \[maximum possible dose of 900 milligrams (mg)\] intravenously infused over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Induction Therapy (every 21 days for 4 cycles): Area Under the Curve (AUC) 6 \[maximum possible dose of 900 milligrams (mg)\] intravenously infused over 30 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Induction Therapy (every 21 days for 4 cycles): 200 mg/m² intravenously infused over 3 hours

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Induction therapy: 15 milligrams/kilogram (mg/kg) given intravenously every 21 days for 4 cycles. Maintenance therapy: 15 mg/kg given intravenously every 21 days until disease progression or treatment discontinuation.
Study: NCT00159965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline
Description: flexible dose sertraline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: flexible dose placebo
Study: NCT04056143

Intervention type: DIAGNOSTIC_TEST
Intervention: Pharmacogenomics
Description: Subjects enrolled in this study are providing blood samples for completing a set of laboratory testing and pharmacogenomic analyses. They are requested to comply a Pharmacist interview and complete of assisted questionnaires.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pharmacogenomics
Description: Subjects enrolled in this study are providing blood samples for completing a set of laboratory testing and pharmacogenomic analyses. They are requested to comply a Pharmacist interview and complete of assisted questionnaires.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pharmacogenomics
Description: Subjects enrolled in this study are providing blood samples for completing a set of laboratory testing and pharmacogenomic analyses. They are requested to comply a Pharmacist interview and complete of assisted questionnaires.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pharmacogenomics
Description: Subjects enrolled in this study are providing blood samples for completing a set of laboratory testing and pharmacogenomic analyses. They are requested to comply a Pharmacist interview and complete of assisted questionnaires.
Study: NCT03932266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: Endostar, 15 mg/m2, continous intravenous infusion, 3 cycles during induction chemotherapy, 4 cycles during concurrent chemoradiotherapy.

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: Cisplatin, 75 mg/m2, intravenous infusion, 3 cycles during induction chemotherapy; Cisplatin, 80 mg/m2, intravenous infusion, 2 cycles during concurrent chemoradiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin, 75 mg/m2, intravenous infusion, 3 cycles during induction chemotherapy; Cisplatin, 80 mg/m2, intravenous infusion, 2 cycles during concurrent chemoradiotherapy.

Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel
Description: Docetaxel, 75 mg/m2, intravenous infusion, 3 cycles during induction chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel, 75 mg/m2, intravenous infusion, 3 cycles during induction chemotherapy.

Intervention type: RADIATION
Group type: OTHER
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Description: IMRT: 66 Gy, 2-2.2 Gy per fraction, a total of 33 fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Description: IMRT: 66 Gy, 2-2.2 Gy per fraction, a total of 33 fractions
Study: NCT03872999

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional brain imaging without any contrast agent
Description: During the functional magnetic resonance imaging (fMRI) protocol, the subject will perform the attentional task while whole-brain activity will be recorded using Echo Planar Imaging (EPI) that measures the Blood Oxygen Level Dependent (BOLD) signal (2x2x2 isotropic voxels, Echo Time (ET) = 30 ms, Repetition Time (RT) = 2.5 sec). The functional session will be subdivided into several parts (Runs, duration: 10-15 min). Together with the functional data, the protocol will include a structural scan (T1 weighted, 1x1x1 mm voxels; duration 5-7 min) and a field mapping sequence (duration: 1 min).
Study: NCT04072588

Intervention type: PROCEDURE
Intervention: vaginal cuff prolapse surgery
Description: Different surgical methods for the treatment of vaginal cuff prolapse in patients who have previously undergone hysterectomy for benign causes

Intervention type: PROCEDURE
Intervention: vaginal cuff prolapse surgery
Description: Different surgical methods for the treatment of vaginal cuff prolapse in patients who have previously undergone hysterectomy for benign causes
Study: NCT03891719

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unilateral cleft lip rhinoplasty
Description: * Perform marking with methylene blue tattoo marks~* Inject Local anesthetic solution with epinephrine~* Harvest auricular cartilage~* Make the incisions parallel the lip scar, extende into the marginal incision and encompass any alar webbing. The incisions outline the entirety of the lower lateral cartilage and create sliding chondrocutaneous flap. This flap combines with reverse U incision.~* Harvest septal bony cartilaginous unit for grafting the caudal septum and suspend the medial crural cartilages~* Create dome symmetry at the cartilage level and reconstruct nasal tip with other grafts (shield-type tip graft, cap graft, alar batten graft)~* Dorsal augmentation~* Lip reconstruction and alar base repositioning.~* Closure and repair vestibular deficiency with the reverse-U component of the chondrocutaneous flap at the alar rim.
Study: NCT02206659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00476606

Intervention type: DRUG
Intervention: Zidovudine, Stavudine, Didanosine, Lamivudine
Description: Refer to the Thai guideline for HIV management 2007

Intervention type: DRUG
Intervention: Nevirapine, Efavirenz
Description: Refer to the Thai guideline for HIV management 2007

Intervention type: DRUG
Intervention: LPV/r, Saquinavir, Indinavir, Ritonavir, Nelfinavir
Description: Refer to the Thai guideline for HIV management 2007
Study: NCT00383890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine HCL Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03734185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Learning and Coping
Description: 'Experienced patients' plan, teach and evaluate, in cooperation with health professionals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Learning and Coping
Description: 'Experienced patients' plan, teach and evaluate, in cooperation with health professionals.
Study: NCT04514393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Intravenous methotrexate at 3.5g/m2 (standard hydration/leucovorin support) will be given on day 1 of all cycles，for up to 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Oral ibrutinib will be given at a dose of 560 mg daily and will be continued daily after completion of methotrexate and temozolomide.Ibrutinib is continued until disease progression, intolerable toxicity or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Oral temozolomide will be given at 150mg/m2 from day1 to day 5 every 4 of all cycles，for up to 4 cycles.
Study: NCT00116922

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avandamet [Rosiglitazone 2mg/Metformin 500mg] BID
Description: \[Rosiglitazone 2mg/ Metformin 500mg\] twice daily
Study: NCT01072942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (Cipro InhaIe, BAYQ3939)
Description: Ciprofloxacin Inhale 50 and 75 mg 2 times a day (BID) for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo TID for 10 days
Study: NCT01968265

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ISIS-GCCRRx
Description: 3 doses on alternate days during the first week and then once weekly for 5 weeks + daily metformin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 doses on alternate days during the first week and then once weekly for 5 weeks + daily metformin
Study: NCT01654107

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Persistence Targeted Smoking Cessation
Description: 8-weeks of smoking cessation counseling (Persistence Targeted Smoking Cessation)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clearing The Air
Description: 8-weeks counseling + 12-weeks nicotine lozenge based on NCI protocol, Clearing The Air

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine lozenge
Description: 12-weeks 4mg nicotine lozenge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Description: 12-weeks 4mg nicotine lozenge
Study: NCT02697409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Against Tobacco intervention